COMP <GO>
CLDX vs LNTH // EV/EBITDA & P/E VALUATION
Celldex Therapeutics Inc. (NASDAQ) VS. Lantheus Holdings Inc. (NASDAQ) • 15-METRIC TALLY: CLDX 2
— LNTH 8
■ METRIC PARITY
LAST: $29.04 (-3.52%) • MKT CAP: $2.36B
valuation
—
LAST: $100.31 (-0.15%) • MKT CAP: $6.56B
valuation
18.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CLDX VS. LNTH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CLDX | LNTH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.10% | 61.10% | +26.00 | CLDX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 20.30% | -55.30 | LNTH | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 18.0x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -9.10% | 4.90% | -14.00 | LNTH | /fcf-yield <GO> |
| Operating Margin | -60.00% | 20.20% | -80.20 | LNTH | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 15.20% | -75.20 | LNTH | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 0.50% | -65.50 | LNTH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 20.25 | 5.34 | +14.91 | CLDX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | LNTH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.7 | 55.8 | -10.10 | LNTH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.88 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 26.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.36B | $6.56B | -$4.19B | LNTH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CLDX REV | LNTH REV | CLDX GROSS % | LNTH GROSS % | CLDX FCF | LNTH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.5M | $1.54B | 87.1% | 61.1% | -$213.7M | $320.8M |
| FY 2024 | $7.0M | $1.53B | 97.2% | 64.4% | -$159.7M | $475.7M |
| FY 2023 | $6.9M | $1.30B | — | — | -$107.3M | $246.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CLDX // BETA —
LNTH // BETA 0.88